Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy

BACKGROUND: Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The difference in outcome between the three drugs has n...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Med
Huvudupphovsmän: Osumi, Hiroki, Shinozaki, Eiji, Ooki, Akira, Wakatsuki, Takeru, Kamiimabeppu, Daisaku, Sato, Taro, Nakayama, Izuma, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Clinical Cancer Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877370/
https://ncbi.nlm.nih.gov/pubmed/33347731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3638
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk